Zimmer Partners LP acquired a new position in shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 15,000 shares of the company's stock, valued at approximately $374,000.
A number of other hedge funds and other institutional investors have also bought and sold shares of the company. T. Rowe Price Investment Management Inc. acquired a new position in Kestra Medical Technologies during the 1st quarter worth about $56,613,000. Omega Fund Management LLC acquired a new position in Kestra Medical Technologies during the 1st quarter worth about $44,754,000. Alliancebernstein L.P. acquired a new position in Kestra Medical Technologies during the 1st quarter worth about $29,500,000. Brown Advisory Inc. acquired a new position in shares of Kestra Medical Technologies in the 1st quarter valued at about $13,716,000. Finally, Millennium Management LLC acquired a new position in shares of Kestra Medical Technologies in the 1st quarter valued at about $11,036,000.
Analyst Ratings Changes
Separately, Wells Fargo & Company dropped their price objective on Kestra Medical Technologies from $28.00 to $27.00 and set an "overweight" rating on the stock in a research note on Thursday, July 17th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $27.33.
Check Out Our Latest Stock Report on Kestra Medical Technologies
Kestra Medical Technologies Price Performance
Kestra Medical Technologies stock traded up $0.97 during trading on Monday, hitting $22.80. The stock had a trading volume of 252,756 shares, compared to its average volume of 276,279. The company's 50 day moving average price is $16.45. Kestra Medical Technologies, Ltd. has a 1 year low of $13.25 and a 1 year high of $26.15. The company has a current ratio of 6.72, a quick ratio of 6.72 and a debt-to-equity ratio of 0.20.
Kestra Medical Technologies Profile
(
Free Report)
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.
Further Reading
Before you consider Kestra Medical Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.
While Kestra Medical Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
